Recombinant human hyaluronidase PH20-mediated dermal spreading activity in mice is not altered by steroids, antihistamines, or salicylic acid.

Journal: Drug metabolism and personalized therapy
Published Date:

Abstract

OBJECTIVES: Drug-drug interaction studies for hyaluronidase safety assessments have evaluated only animal-derived enzyme preparations. We therefore set out to evaluate whether high-dose administration of two antihistamines, a potent corticosteroid, steroid hormone, adrenocorticotropic hormone (ACTH), or salicylic acid would alter the dispersive activity of recombinant human hyaluronidase PH20 (rHuPH20).

Authors

  • Jessica A Cowell
    Halozyme Therapeutics Inc., San Diego, CA, USA.
  • Marie A Printz
    Halozyme Therapeutics Inc., San Diego, CA, USA.
  • Curtis B Thompson
    Halozyme Therapeutics Inc., San Diego, CA, USA.

Keywords

No keywords available for this article.